DWTI announces new members for board of directors

Japan Patent Office to confirm Rho-kinase inhibitor patent.

DWTI announces a change in president position.

K-134 has been presented as a PDE3 inhibitor with its less-hemorrhagic mechanism suggestion at the 31st Congress of The Japanese Society on Thrombosis and Hemostasis.

European Patent Office to confirm Rho-kinase inhibitor patent.

K-134 has been presented as a PDE3 inhibitor at the 17th Annual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics.

DWTI to contract collaborative research agreement with RIKEN.